ANDA 210536, held by Alembic. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 210536 (Doxycycline Hyclate), held by Alembic, was first approved by FDA on May 14, 2020, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 14, 2020 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 50MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Aug 13, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 13, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 14, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters